Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.38 |
| ▸ | JAK1 | P23458 | 2/20 | 0.38 |
| ▸ | JAK3 | P52333 | 2/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 17/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 9/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL566656 | 0.87 | JAK2 (0.43) | JAK2JAK1JAK3TYK2SCN9A | |
| SCHEMBL16477542 | 0.82 | JAK2 (0.46) | JAK2JAK1JAK3TYK2SCN9A | |
| SCHEMBL14708549 | 0.81 | JAK2 (0.40) | JAK2JAK1JAK3TYK2SCN9A | |
| SCHEMBL14708547 | 0.79 | JAK2 (0.40) | JAK2JAK1JAK3TYK2SCN9A | |
| SCHEMBL18362951 | 0.79 | SCN9A (0.38) | JAK2JAK1JAK3TYK2SCN9A | |
| SCHEMBL16477545 | 0.79 | SCN9A (0.38) | JAK2JAK1JAK3TYK2SCN9A | |
| SCHEMBL10099139 | 0.78 | SCN9A (0.42) | JAK2JAK1JAK3TYK2SCN9A | |
| SCHEMBL14708584 | 0.77 | JAK2 (0.37) | JAK2JAK1JAK3TYK2SCN9A | |
| SCHEMBL16477554 | 0.76 | JAK2 (0.45) | JAK2JAK1JAK3TYK2SCN9A | |
| SCHEMBL16477544 | 0.75 | SCN9A (0.39) | JAK1SCN9ASCN5AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2420502-A1 | FUSED PYRROLOPYRIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20120034250-A1 | CONDENSED PYRROLOPYRIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-02-09 | — | — | US | disclosed |
| US-20120034250-A1 | CONDENSED PYRROLOPYRIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120034250-A1 | CONDENSED PYRROLOPYRIDINE DERIVATIVE | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885JAK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.